Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis.

Background: Remdesivir, molnupiravir, and nirmatrelvir/ritonavir are three antiviral agents approved by FDA emergency authorization for treating mild to moderate symptomatic COVID-19 adult outpatients at high risk for hospitalization and death.

Objectives: To compare the efficacy and safety of these antivirals based on updated published RCT and real-world data.

Study Design: This systematic review followed the preferred reporting items for systematic reviews and meta-analysis framework guidelines.